The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival Outcome

Abstract

Objective: To evaluate the impact of pathogenic BRCA1/2 tumor mutation on advanced stage-high grade serous epithelial ovarian cancer (HGSOC) survival outcome. Methods: A total of 68 from 144 patients were diagnosed with FIGO 2014 stage IIB-IV HGSOC between January 1st 2015, until March 31st 2021, at Dr. Cipto Mangunkusumo National Central Referral Hospital, Persahabatan Central Referral Hospital, and MRCCC Central Referral Hospital Siloam Jakarta, underwent NGS tumor BRCA1/2 gene testing and were included in this cohort historical study. We compared patient’s overall survival outcomes to pathogenic BRCA1/2 tumor mutational status. The patient’s clinicopathological characteristic factors that might affect patient’s survival outcomes were also investigated. Results: In the group with pathogenic BRCA1/2 tumor mutation, the likelihood of dying was 86% ​​lower (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001), and the median survival was better (median 46 months; 95%CI 34.009-57.991; p value=0.001) than the group without pathogenic BRCA1/2 tumor mutations (median 23 months; 95%CI 15.657-30.343; p value=0.001). The multivariate analyses identified pathogenic BRCA1/2 tumor mutation as an independent favorable prognostic factor for survival outcome (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001).Conclusions: In advanced stage-HGSOC patients, the pathogenic BRCA1/2 tumor mutations group have a better prognosis with longer survival outcomes than those without pathogenic BRCA1/2 tumor mutations.